Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Cardona

Showing results (221-230 of 333) with videos related to

Pageof 34
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II studyOscar Arrieta, Feliciano Barrón, Federico Maldonado, et al.
Therapeutic Advances in Respiratory Disease|January 31, 2022
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' blockJuan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Probable hereditary familial overlap syndrome with multiple synchronous lung tumorsAndrés F Cardona, Zyanya Lucia Zatarain-Barrón, Cladelis Rubio, et al.
Nature Communications|May 16, 2025
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trialOscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, et al.
Nature Communications|December 12, 2025
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trialOscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, et al.
The Oncologist|March 4, 2025
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)Erick F Saldanha, Vladmir C Cordeiro de Lima, Aline Fares, et al.
Thoracic Cancer|November 1, 2022
Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancerAlejandro Avilés-Salas, Diana Flores-Estrada, Luis Lara-Mejía, et al.
Journal of the Neurological Sciences|June 12, 2016
Refractoriness to pharmacological treatment for tics: A multicentre European auditA Macerollo, D Martino, A E Cavanna, et al.
Cancer|January 3, 2014
Distribution and trends of hematology and oncology research in Latin America: A decade of uncertaintyAndrés M Acevedo, Alexandra Gómez, Henry A Becerra, et al.
Translational Lung Cancer Research|June 19, 2025
Visceral crisis in a patient with non-small cell lung cancer and <i>ROS1::SDC4</i> fusion: intrinsic resistance to entrectinib via L2026M mutation-a case reportVaneza Avila Rodriguez, Nicolle Wagner-Gutiérrez, Jairo Andrés Zuluaga León, et al.
Pageof 34

Showing results (221-230 of 333) with videos related to

Sort By:
Pageof 34
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II studyOscar Arrieta, Feliciano Barrón, Federico Maldonado, et al.
Therapeutic Advances in Respiratory Disease|January 31, 2022
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' blockJuan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Probable hereditary familial overlap syndrome with multiple synchronous lung tumorsAndrés F Cardona, Zyanya Lucia Zatarain-Barrón, Cladelis Rubio, et al.
Nature Communications|May 16, 2025
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trialOscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, et al.
Nature Communications|December 12, 2025
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trialOscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, et al.
The Oncologist|March 4, 2025
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)Erick F Saldanha, Vladmir C Cordeiro de Lima, Aline Fares, et al.
Thoracic Cancer|November 1, 2022
Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancerAlejandro Avilés-Salas, Diana Flores-Estrada, Luis Lara-Mejía, et al.
Journal of the Neurological Sciences|June 12, 2016
Refractoriness to pharmacological treatment for tics: A multicentre European auditA Macerollo, D Martino, A E Cavanna, et al.
Cancer|January 3, 2014
Distribution and trends of hematology and oncology research in Latin America: A decade of uncertaintyAndrés M Acevedo, Alexandra Gómez, Henry A Becerra, et al.
Translational Lung Cancer Research|June 19, 2025
Visceral crisis in a patient with non-small cell lung cancer and <i>ROS1::SDC4</i> fusion: intrinsic resistance to entrectinib via L2026M mutation-a case reportVaneza Avila Rodriguez, Nicolle Wagner-Gutiérrez, Jairo Andrés Zuluaga León, et al.
Pageof 34